Cargando…
Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma
Histone deacetylase 6 (HDAC6) is an epigenetic modifier that is an attractive pharmacological target in cancer. In this work, we show that HDAC6 is elevated in glioblastoma, the most malignant and common brain tumor in adults, in which its high levels correlate with poor patient survival and is more...
Autores principales: | Auzmendi-Iriarte, Jaione, Saenz-Antoñanzas, Ander, Mikelez-Alonso, Idoia, Carrasco-Garcia, Estefania, Tellaetxe-Abete, Maitena, Lawrie, Charles H., Sampron, Nicolás, Cortajarena, Aitziber L., Matheu, Ander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265429/ https://www.ncbi.nlm.nih.gov/pubmed/32488056 http://dx.doi.org/10.1038/s41419-020-2586-x |
Ejemplares similares
-
Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
por: Saenz-Antoñanzas, Ander, et al.
Publicado: (2019) -
Impact of Chaperone-Mediated Autophagy in Brain Aging: Neurodegenerative Diseases and Glioblastoma
por: Auzmendi-Iriarte, Jaione, et al.
Publicado: (2021) -
CRISPR/Cas9 Deletion of SOX2 Regulatory Region 2 (SRR2) Decreases SOX2 Malignant Activity in Glioblastoma
por: Saenz-Antoñanzas, Ander, et al.
Publicado: (2021) -
Chaperone-Mediated Autophagy Controls Proteomic and Transcriptomic Pathways to Maintain Glioma Stem Cell Activity
por: Auzmendi-Iriarte, Jaione, et al.
Publicado: (2022) -
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
por: Egaña, Larraitz, et al.
Publicado: (2020)